{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:03:45Z","timestamp":1787695425062,"version":"build-2784847793"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["NIDDK T32DK007202"],"award-info":[{"award-number":["NIDDK T32DK007202"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,24]]},"DOI":"10.1093\/ecco-jcc\/jjx130","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T15:13:23Z","timestamp":1505488403000},"page":"167-177","source":"Crossref","is-referenced-by-count":60,"title":["Development of Clinical Prediction Models for Surgery and Complications in Crohn\u2019s Disease"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5864-8422","authenticated-orcid":false,"given":"Leonardo","family":"Guizzetti","sequence":"first","affiliation":[{"name":"Robarts Clinical Trials Inc., University of Western Ontario, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada"},{"name":"Robarts Clinical Trials Inc., University of Western Ontario, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, ON, Canada"},{"name":"Robarts Clinical Trials Inc., University of Western Ontario, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parambir S","family":"Dulai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials Inc., University of Western Ontario, London, ON, Canada"},{"name":"Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada"},{"name":"Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, ON, Canada"},{"name":"Robarts Clinical Trials Inc., University of Western Ontario, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada"},{"name":"Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, ON, Canada"},{"name":"Robarts Clinical Trials Inc., University of Western Ontario, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"key":"key\n\t\t\t\t20180315032336_CIT0001","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/00365520601076124","article-title":"Clinical course in Crohn\u2019s disease: results of a five-year population-based follow-up study [the IBSEN study]","volume":"42","author":"Henriksen","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0003","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0004","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ajg.2012.298","article-title":"Surgery in a population-based cohort of Crohn\u2019s disease from Olmsted County, Minnesota [1970\u20132004]","volume":"107","author":"Peyrin-Biroulet","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0005","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","article-title":"Clinical course in Crohn\u2019s disease: results of a Norwegian population-based ten-year follow-up study","volume":"5","author":"Solberg","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180315032336_CIT0006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0007","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180315032336_CIT0008","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032336_CIT0010","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180315032336_CIT0011","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/apt.12930","article-title":"Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn\u2019s disease: 7-year results from the PRECiSE 3 study","volume":"40","author":"Sandborn","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180315032336_CIT0012","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/ajg.2010.78","article-title":"Increased response and remission rates in short-duration Crohn\u2019s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomised maintenance trial data","volume":"105","author":"Schreiber","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0013","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032336_CIT0014","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032336_CIT0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032336_CIT0016","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0017","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0018","article-title":"Long-term efficacy of vedolizumab for Crohn\u2019s disease","author":"Vermeire","year":"2017;11:412\u201324","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180315032336_CIT0019","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032336_CIT0020","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180315032336_CIT0021","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease [REACT]: a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180315032336_CIT0022","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180315032336_CIT0023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11938-016-0085-z","article-title":"Advances in therapeutic drug monitoring of biologic therapies in inflammatory bowel disease: 2015 in review","volume":"14","author":"Scott","year":"2016","journal-title":"Curr Treat Options Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0024","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: Deep remission in biologic and immunomodulator nai ve patients with Crohn\u2019s disease - a sonic post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180315032336_CIT0026","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cgh.2013.06.019","article-title":"Adalimumab induces deep remission in patients with Crohn\u2019s disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180315032336_CIT0027","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032336_CIT0028","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn\u2019s disease patients: a randomised placebo-controlled trial","volume":"130","author":"L\u00e9mann","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0029","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0030","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000358132","article-title":"Can we predict the high-risk patient","volume":"32","author":"Benitez","year":"2014","journal-title":"Dig Dis"},{"key":"key\n\t\t\t\t20180315032336_CIT0031","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s11605-013-2250-1","article-title":"An envirogenomic signature is associated with risk of IBD-related surgery in a population-based Crohn\u2019s disease cohort","volume":"17","author":"Nasir","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"key\n\t\t\t\t20180315032336_CIT0032","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of Crohn\u2019s disease","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0033","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/00365520801957149","article-title":"Predictors of severe Crohn\u2019s disease","volume":"43","author":"Loly","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0034","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/gut.2009.202101","article-title":"Natural history of Crohn\u2019s disease in a population-based cohort from Cardiff [1986\u20132003]: A study of changes in medical treatment and surgical resection rates","volume":"59","author":"Ramadas","year":"2010","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180315032336_CIT0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ajg.2008.38","article-title":"Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease","volume":"104","author":"Romberg-Camps","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0036","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/apt.12368","article-title":"Predicting complicated Crohn\u2019s disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort","volume":"38","author":"Ryan","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180315032336_CIT0037","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1111\/j.1572-0241.2008.02212.x","article-title":"Perianal disease predicts changes in Crohn\u2019s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype","volume":"103","author":"Tarrant","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0038","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn\u2019s disease in a population-based cohort","volume":"139","author":"Thia","year":"2010","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0039","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/gut.2005.084061","article-title":"Phenotype at diagnosis predicts recurrence rates in Crohn\u2019s disease","volume":"55","author":"Wolters","year":"2006","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180315032336_CIT0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1751-2980.2011.00484.x","article-title":"Risk factors that predict the requirement of aggressive therapy among Chinese patients with Crohn\u2019s disease","volume":"12","author":"Yang","year":"2011","journal-title":"J Dig Dis"},{"key":"key\n\t\t\t\t20180315032336_CIT0041","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MIB.0b013e318281f275","article-title":"Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn\u2019s disease","volume":"19","author":"Dubinsky","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180315032336_CIT0042","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/ecco-jcc\/jjv127","article-title":"Risk matrix for prediction of disease progression in a referral cohort of patients with Crohn\u2019s disease","volume":"9","author":"Lakatos","year":"2015","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180315032336_CIT0043","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/apt.13460","article-title":"A validated web-based tool to display individualised Crohn\u2019s disease predicted outcomes based on clinical, serologic and genetic variables","volume":"43","author":"Siegel","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180315032336_CIT0044","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/01.MIB.0000436956.78220.67","article-title":"Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn\u2019s Disease [the IBSEN Study]","volume":"20","author":"Solberg","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180315032336_CIT0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.114.014508","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis [TRIPOD]: the TRIPOD statement. The TRIPOD Group","volume":"131","author":"Collins","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180315032336_CIT0046","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2288-13-19","article-title":"Prediction models for clustered data: comparison of a random intercept and standard regression model","volume":"13","author":"Bouwmeester","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"key\n\t\t\t\t20180315032336_CIT0047","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies","author":"Harrell","year":"2015"},{"key":"key\n\t\t\t\t20180315032336_CIT0048","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-77244-8","volume-title":"Clinical Prediction Models","author":"Steyerberg","year":"2009"},{"key":"key\n\t\t\t\t20180315032336_CIT0049","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0272989X9301300107","article-title":"Validation of probabilistic predictions","volume":"13","author":"Miller","year":"1993","journal-title":"Med Decis Making"},{"key":"key\n\t\t\t\t20180315032336_CIT0050","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20180315032336_CIT0051","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/01621459.1986.10478291","article-title":"How biased is the apparent error rate of a prediction rule","volume":"81","author":"Efron","year":"1986","journal-title":"J Am Stat Assoc"},{"key":"key\n\t\t\t\t20180315032336_CIT0052","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jclinepi.2015.02.002","article-title":"A simulation study of sample size demonstrated the importance of the number of events per variable to develop prediction models in clustered data","volume":"68","author":"Wynants","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"key\n\t\t\t\t20180315032336_CIT0053","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2016"},{"key":"key\n\t\t\t\t20180315032336_CIT0054","volume-title":"Rstudio: Integrated Development Environment for r","author":"R Studio Team","year":"2015"},{"key":"key\n\t\t\t\t20180315032336_CIT0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: Current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180315032336_CIT0056","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: Part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180315032336_CIT0057","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00000658-200001000-00006","article-title":"Risk factors for surgery and postoperative recurrence in Crohn\u2019s disease","volume":"231","author":"Bernell","year":"2000","journal-title":"Ann Surg"},{"key":"key\n\t\t\t\t20180315032336_CIT0058","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.3748\/wjg.v21.i23.7272","article-title":"Prevalence and predictors of hospitalisation in Crohn\u2019s disease in a prospective population-based inception cohort from 2000\u20132012","volume":"21","author":"Golovics","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0059","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3748\/wjg.v19.i14.2217","article-title":"Evolution of disease phenotype in adult and pediatric onset Crohn\u2019s disease in a population-based cohort","volume":"19","author":"Lovasz","year":"2013","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032336_CIT0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.gastro.2011.03.050","article-title":"Outcomes of patients with Crohn\u2019s disease improved from 1988 to 2008 and were associated with increased specialist care","volume":"141","author":"Nguyen","year":"2011","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032336_CIT0061","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","article-title":"Towards better clinical prediction models: seven steps for development and an ABCD for validation","volume":"35","author":"Steyerberg","year":"2014","journal-title":"Eur Heart J"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/12\/2\/167\/24365593\/jjx130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T11:02:24Z","timestamp":1570100544000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/12\/2\/167\/4161635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,9,19]]},"published-print":{"date-parts":[[2018,1,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx130","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,9,19]]}}}